NCCN Guidelines® Insights - Prostate Cancer, Version 1.2023
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, recurrent, and metastatic disease. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. These NCCN Guidelines Insights summarizes much of the panel’s discussions for the 4.2022 and 1.2023 updates to the guidelines regarding systemic therapy for metastatic prostate cancer.
This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Prostate Cancer
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Prostate Cancer
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Individuals Who Provided Content Development and/or Authorship Assistance
The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.
Ryan A. Berardi, MSc, Guidelines Layout Specialist, NCCN
Deborah A. Freedman-Cass, PhD, Manager, Guidelines Processes, NCCN
Dorothy A. Shead, MS, Senior Director, Patient Information Operations, NCCN
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Edward M. Schaeffer, MD, PhD, Panel Chair, has disclosed serving as a scientific advisor for AbbVie, Inc., Astellas Pharma US, Inc., Janssen Scientific Affairs, LLC, Lantheus, and Pfizer, Inc.
Sandy Srinivas, MD, Panel Vice Chair, has disclosed serving as a scientific advisor for Bayer HealthCare, Janssen Pharmaceutica Products, LP, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation; and receiving grant/research support from Bayer HealthCare, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.
Brian Chapin, MD, Panel Member, has disclosed serving as a scientific advisor for Janssen Pharmaceutica Products, LP, Merck & Co., Inc., and Pfizer Inc.; receiving grant/research support from Blue Earth Diagnostics and Regeneron Pharmaceuticals, Inc.; and receiving consulting fees from Johnson & Johnson.
Rana R. McKay, MD, Panel Member, has disclosed receiving consulting fees from AstraZeneca Pharmaceuticals LP, AVEO Pharmaceuticals, Inc., Bayer HealthCare, Bristol-Myers Squibb Company, Calithera Biosciences Inc., Caris Life Sciences, Dendreon Corporation, Exelixis Inc., Janssen Pharmaceutica Products, LP, Merck & Co., Inc., Myovant Sciences, Novartis Pharmaceuticals Corporation, Pfizer Inc., sanofi-aventis US, SeaGen, Sorrento Therapeutics, Inc., Telix Pharmaceuticals Limited, and Tempus Labs, Inc.; and receiving grant/research support from Bayer HealthCare.
Daniel Spratt, MD, Panel Member, has disclosed receiving honorarium from Blue Earth Diagnostics, Novartis Pharmaceuticals Corporation, Pfizer Inc., and Varian Medical Systems, Inc.; and receiving consulting fees from Bayer HealthCare.
Benjamin A. Teply, MD, Panel Member, has disclosed receiving consulting fees from AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Hospicom Inc., sanofi-aventis U.S., and SeaGen; receiving grant/research support from Bellicum Pharmaceuticals, Inc., Bristol-Myers Squibb Company, and QED Pharmaceutical Services, LLC; and serving as a scientific advisor for Pfizer Inc.
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-22-012-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until December 10, 2023. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation